Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.
Tositumomab/iodine-131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin) are radioimmunoconjugates targeting the CD20 antigen. Both agents are approved in the United States for use in relapsed or refractory, indolent or transformed, B-cell lymphoma. These agents are well tolerated and have the highest levels of single-agent activity observed in these histologies. This review will summarize the key trials that led to approval of both I-131 tositumomab and ibritumomab tiuxetan, and then focus on four novel therapeutic concepts in radioimmunotherapy: retreatment, therapy of de novo indolent lymphoma, therapy of aggressive histologies, and incorporation in high-dose therapy programs utilizing autologous stem cell support.
Schaefer-Cutillo
Julia
J
James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA.
Friedberg
Jonathan W
JW
Fisher
Richard I
RI
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D016499:Radioimmunotherapy; D033581:Stem Cell Transplantation; D014481:United States / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors; C422802:ibritumomab tiuxetan; C119496:tositumomab I-131